● Recruiting

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Condition: Breast Neoplasms · Breast Cancer · Neoplasm Metastasis · Sponsor: AstraZeneca

PhaseN/A

Planned participants800

Who can joinAll sexes, 18 Years to 130 Years

Healthy volunteersNo

About this study

This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with documented Human epidermal growth factor receptor 2 (HER2)-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer (BC) receiving T-DXd in line with the applicable summary of product characteristics (SmPC) within routine clinical practice in Germany. In addition, patients will be informed about use of digital healthcare application (DiGA).

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (108)

Research Site	Amberg, Germany	Withdrawn
Research Site	Ansbach, Germany	Withdrawn
Research Site	Apolda, Germany	Recruiting
Research Site	Aschaffenburg, Germany	Recruiting
Research Site	Augsburg, Germany	Recruiting
Research Site	Augsburg, Germany	Recruiting
Research Site	Bad Reichenhall, Germany	Recruiting
Research Site	Baden-Baden, Germany	Recruiting
Research Site	Balingen, Germany	Recruiting
Research Site	Bamberg, Germany	Recruiting
Research Site	Berlin, Germany	Recruiting
Research Site	Berlin, Germany	Recruiting

+ 96 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05573893